{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:31:39Z","timestamp":1788193899549,"version":"build-2803163510"},"reference-count":12,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T00:00:00Z","timestamp":1705622400000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Recent data suggest that ursodeoxycholic acid (UDCA) therapy may reduce susceptibility to severe acute respiratory syndrome coronavirus 2\u00a0(SARS\u2010CoV\u20102) infection and even improve clinical outcomes when coronavirus disease\u20102019\u00a0(COVID\u201019) was diagnosed. However, clinical evidence of UDCA's ability to prevent severe forms of COVID\u201019 remains limited and contradictory. We evaluated the association between UDCA exposure and the risk of hospitalization for COVID\u201019 in a large multicenter population of patients with chronic liver disease (CLD) followed during the pandemic period before vaccination. An exposed\/unexposed cohort study and a nested case\u2013control study were performed. The primary endpoint was severe COVID\u201019, defined as SARS\u2010CoV2 infection requiring hospitalization. The secondary endpoint was COVID\u201019\u2010associated intensive care unit (ICU) admission or death. Adjusted odds ratios (aOR) and their confidence intervals (CI) were determined after controlling for age, gender, comorbidities at risk for COVID\u201019, severity of CLD, and prior hospitalizations. A total of 10\u2009147 patients, including 1322 exposed and 8825 not exposed to UDCA, totaling 21\u2009867 person\u2010years of follow\u2010up, were included in the cohort analysis, while 88 patients hospitalized for COVID\u201019 and 840 matched controls were eligible for the nested case\u2013control analysis. In both analyses, exposure to UDCA was not associated with a significant reduction in the risk of hospitalization for COVID\u201019, with aOR (95% confidence interval) values of 0.48 (0.20\u20131.19) and 0.93 (0.26\u20133.29), respectively. Furthermore, there was no significant reduction in the risk of ICU admission or death. In this large population of patients with CLD, UDCA exposure was not associated with a reduced risk of severe COVID\u201019.<\/jats:p>","DOI":"10.1002\/jmv.29418","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T12:18:39Z","timestamp":1705666719000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Exploring the impact of ursodeoxycholic acid therapy on COVID\u201019 in a real\u2010world setting"],"prefix":"10.1002","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7920-9784","authenticated-orcid":false,"given":"Christophe","family":"Corpechot","sequence":"first","affiliation":[{"name":"Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis, European Reference Network on Hepatological Diseases (ERN Rare\u2010Liver), Saint\u2010Antoine Hospital Assistance Publique\u2010H\u00f4pitaux de Paris (AP\u2010HP) Paris France"},{"name":"Inserm UMR_S938, Saint\u2010Antoine Research Center Sorbonne University Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Verdoux","sequence":"additional","affiliation":[{"name":"Clinical Research Unit, Direction of Clinical Research, Bic\u00eatre Hospital, AP\u2010HP Paris\u2010Saclay University Le Kremlin\u2010Bic\u00eatre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Frank\u2010Soltysiak","sequence":"additional","affiliation":[{"name":"Medical Informatics Department, Bic\u00eatre Hospital, AP\u2010HP Paris\u2010Saclay University Le Kremlin\u2010Bic\u00eatre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Charles","family":"Duclos\u2010Vall\u00e9e","sequence":"additional","affiliation":[{"name":"F\u00e9d\u00e9ration Hospitalo\u2010Universitaire H\u00e9patinov, Inserm UMR_S 1193, Paul Brousse Hospital, AP\u2010HP Paris\u2010Saclay University Villejuif France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamiae","family":"Grimaldi","sequence":"additional","affiliation":[{"name":"Clinical Research Unit, Direction of Clinical Research, Bic\u00eatre Hospital, AP\u2010HP Paris\u2010Saclay University Le Kremlin\u2010Bic\u00eatre France"},{"name":"Inserm UMR1018 Anti\u2010Infective Evasion and Pharmacoepidemiology,\u00a0Simone Veil School of Medicine Paris\u2010Saclay University Montigny\u2010Le\u2010Bretonneux France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,1,19]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05594-0"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13630"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1178590"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcad254"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/v15081738"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15736"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15660"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmpb.2018.10.016"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41746-020-00308-0"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.2196\/20773"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-325700"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ueg2.12100"}],"updated-by":[{"DOI":"10.1002\/jmv.29518","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000}}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.29418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T23:19:45Z","timestamp":1743895185000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.29418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1002\/jmv.29418"],"URL":"https:\/\/doi.org\/10.1002\/jmv.29418","archive":["Portico"],"relation":{"correction":[{"id-type":"doi","id":"10.1002\/jmv.29518","asserted-by":"object"}]},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2023-12-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e29418"}}